IO Primer: Immune-Related Adverse Events: This brief knowledge-building module reviews the mechanisms of immune-related adverse events (irAEs) and provides practical strategies for managing irAEs in clinical practice.
The IO Toxicity Tool integrates guideline recommendations on the management of immune-related adverse events (irAEs) from the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN) and Society for Immunotherapy of Cancer (SITC).
Jacobson A, Macfarlane CL, Pozniak E (2020) Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care. JECME. 9:1, 1834762, DOI: 10.1080/21614083.2020.1834762
With rapid advances in cancer treatment, oncologists and their clinical teams are challenged to keep pace with the latest evidence and standards of care. The Oncology Clinic Companion provides independent medical education and practical tools designed to increase knowledge, competence and performance among oncology professionals. About Oncology Clinic Companion.
The brief knowledge-building modules review essential topics in immuno-oncology (IO), including the immune system and cancer therapy, mechanisms of action of immune checkpoint inhibitors, assessing response to IO therapy and immune-related adverse events.
The case challenges explore the role of checkpoint inhibitor therapy in the management of cancer, including advanced renal cancer, advanced bladder cancer, advanced melanoma and Hodgkin lymphoma.
The webcast modules, recorded at the ECOS 2019 meeting, feature cardio-oncology experts holding multidisciplinary sessions with interactive discussion and case reviews.
Test and build your knowledge of core concepts in immuno-oncology (IO) therapy with challenging patient cases in cancer, including bladder, lung, colorectal and kidney cancer, as well as lymphoma and melanoma.
Tweets by OncClinComp
What is the future of IO therapy in renal and bladder cancers? Listen as EIOCC faculty Maria Carmen Mir, MD, PhD, and Mario W. Kramer, MD, discuss the emerging role of immune checkpoint inhibitors in patient care.
The University of Manchester Innovation Centre (UMIC)